Early hydroxychloroquine and azithromycin as combined therapy for COVID-19: a case series

Early hydroxychloroquine and azithromycin as combined therapy for COVID-19: a case series

Coronavirus disease 2019 (COVID-19) is a worldwide outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) has declared it as a public health emergency of international concern (PHEIC) and eventually a pandemic. Many clinical trials have b...

Full description

Bibliographic Details
Main Authors:	Siswanto Siswanto, Oktaviarum S. Utama, Agit S. Adisetiadi, Maria E. Pranasakti, Mohamad Saifudin Hakim
Format:	Article
Language:	English
Published:	Universitas Gadjah Mada 2020-06-01
Series:	Journal of the Medical Sciences
Subjects:	azithromycin covid-19 hydroxychloroquine sars-cov-2 therapy
Online Access:	https://jurnal.ugm.ac.id/bik/article/view/56441

Similar Items

Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-19
by: Filippo Albani, et al.
Published: (2020-08-01)

Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?
by: Chunfeng Li, et al.
Published: (2020-08-01)

Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia
by: Nobuaki Mori, et al.
Published: (2021-02-01)

Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients
by: Matthieu MILLION, et al.
Published: (2021-09-01)

A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: Results of a retrospective observational study in the French overseas department of Réunion Island
by: Arthur Dubernet, et al.
Published: (2020-12-01)

Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020
by: Fabien Taieb, et al.
Published: (2021-06-01)

Systematic review and meta-analysis of efficacy and safety of hydroxychloroquine and chloroquine in the treatment of COVID-19
by: Niti Mittal, et al.
Published: (2021-01-01)

Hydroxychloroquine and azithromycin use in COVID-19 era and cardiovascular concerns: Current perspective
by: Aditya Kapoor, et al.
Published: (2021-01-01)

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
by: Samia Arshad, et al.
Published: (2020-08-01)

Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review
by: C. Prodromos, et al.
Published: (2020-11-01)

Effects of cardiac toxicity of combination therapy with hydroxychloroquine and azithromycin in COVID-19 patients
by: Usha Yendrapalli, et al.
Published: (2021-11-01)

Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)—protocol of randomised controlled trial AZIQUINE-ICU
by: František Duška, et al.
Published: (2020-07-01)

Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance
by: R. Choudhary, et al.
Published: (2020-05-01)

Proarrhythmia assessment in treatment with hydroxychloroquine and azithromycin hospitalized elderly COVID-19 patients - our experience
by: Raffaele Costa, et al.
Published: (2021-06-01)

Hydroxychloroquine is protective to the heart, not harmful: a systematic review
by: C.C. Prodromos, et al.
Published: (2020-09-01)

Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine
by: Bianza Moise Bakadia, et al.
Published: (2021-01-01)

Mitigating arrhythmia risk in Hydroxychloroquine and Azithromycin treated COVID-19 patients using arrhythmia risk management plan
by: Kazimieras Maneikis, et al.
Published: (2021-02-01)

Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19
by: Elisa Baranski Lamback, et al.
Published: (2021-03-01)

QT interval and repolarization dispersion changes during the administration of hydroxychloroquine/chloroquine with/without azithromycin in early COVID 19 pandemic: A prospective observational study from two academic hospitals in Indonesia
by: Rizki A. Gumilang, et al.
Published: (2021-10-01)

Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial
by: Christine Johnston, et al.
Published: (2021-03-01)

QTc Prolongation Risk Evaluation in Female COVID-19 Patients Undergoing Chloroquine and Hydroxychloroquine With/Without Azithromycin Treatment
by: Sarah Grewal, et al.
Published: (2020-09-01)

Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial
by: Javed Akram, et al.
Published: (2020-08-01)

Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al
by: Mondher Toumi, et al.
Published: (2020-01-01)

Drug Interactions and Side Effects of Co-Administration of Chloroquine/Hydroxychloroquine and Azithromycin: on the Issue of Rational Pharmacotherapy of Patients with COVID-19 with Antimalarial Drugs
by: O. V. Gaisenok
Published: (2020-07-01)

Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses
by: Peng Liu, et al.
Published: (2020-01-01)

Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan
by: Pradeesh Sivapalan, et al.
Published: (2020-10-01)

Study of the structural, chemical descriptors and optoelectronic properties of the drugs Hydroxychloroquine and Azithromycin
by: G.W. Ejuh, et al.
Published: (2020-08-01)

Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients
by: A.J.J. Lammers, et al.
Published: (2020-12-01)

Hydroxychloroquine: A Familiar Agent to Combat the Pandemic of COVID-19
by: Vasilios M. Polymeropoulos
Published: (2020-04-01)

The impact of hydroxychloroquine–azithromycin combination on Tpeak‐to‐end and Tpeak‐to‐end/QT ratio during a short treatment course
by: Nijad Bakhshaliyev, et al.
Published: (2021-07-01)

Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial
by: Pradeesh Sivapalan, et al.
Published: (2020-06-01)

Role of hydroxychloroquine in multidrug treatment of COVID-19
by: Peter A. McCullough, et al.
Published: (2021-09-01)

No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19
by: Kenneth Sands, et al.
Published: (2021-03-01)

Therapeutic Options for Coronavirus Disease 2019 (COVID-19) - Modulation of Type I Interferon Response as a Promising Strategy?
by: Aurélien Mary, et al.
Published: (2020-05-01)

QT interval measurement with portable device during COVID-19 outbreak
by: Nerea Torres González, et al.
Published: (2020-10-01)

The Rise and Fall of Chloroquine/Hydroxychloroquine as Compassionate Therapy of COVID-19
by: Elangovan Manivannan, et al.
Published: (2021-05-01)

Hydroxychloroquine in the treatment of COVID-19 disease: a systematic review and meta-analysis
by: Amahirany Manzo-Toledo, et al.
Published: (2021-01-01)

Hydroxychloroquine in COVID-19 Patients: Pros and Cons
by: Nour K. Younis, et al.
Published: (2020-11-01)

The study of cardiotoxicity of hydroxychloroquine and azithromycine combination in hospitalized patients with COVID-19
by: Yu. N. Belenkov, et al.
Published: (2020-12-01)

Chloroquine and hydroxychloroquine in the context of COVID-19
by: Ashutosh M Shukla, et al.
Published: (2020-04-01)